BLUE BELL, Pa., Sept. 6, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the interim analysis of its SynCon® universal H1N1 influenza vaccine showed that it generated protective HAI titers against some of the most prevalent strains of H1N1 influenza from the past 100 years in a phase I clinical trial. Because the SynCon® approach incorporates sequence information from multiple divergent strains, the vaccine is not matched to any of the historical flu strains. The achievement of protective titers against multiple unmatched strains represents a major step towards Inovio's ultimate goal to develop a universal influenza vaccine to protect against known and newly emerging strains of influenza.
"With respect to influenza, our ultimate objective is to develop a universal vaccine capable of providing years of true preemptive protection across subtypes and strains," said Dr. J. Joseph Kim, Inovio's President and CEO. "This is a challenging goal but this proof-of-principle H1N1 data demonstrates the potential of our SynCon® approach to generate cross-protective HAI titers against multiple unmatched influenza strains. These results are an important addition to our previously reported H5N1 phase I data and a validating achievement on our ongoing effort to develop a safe vaccine that provides immunity against the ever-changing influenza virus."
The current open label phase I study evaluated two synthetic H1N1 hemagglutinin (HA) plasmids designed to broadly protect against unmatched influenza strains within different branches of the H1N1 subtype. These plasmids were delivered in healthy adults with Inovio's CELLECTRA® intradermal electroporation device up to three times. The delivered vaccine was well tolerated; reported adverse events and injection site reactions were mild to moderate and required no treatment.
Researchers exposed blood samples from the vaccinated subjects to each of the ni